# Safety and Efficacy of Zicronapine in Patients With Schizophrenia

> **NCT01295372** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 160 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Zicronapine
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT01295372
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-10
- **Final completion:** —
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2016-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01295372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01295372, "Safety and Efficacy of Zicronapine in Patients With Schizophrenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01295372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*